Monday, June 15, 2026

U.S. Hits Chinese Battery Supplier With Shocking 712% Tariff

The U.S. plans a 712% duty on Huizhou Kaixin, boosting South Korean battery firms while raising concerns over production costs.

How North Korean Youth Are Leading Revolutionary Change: Insights from the 80th Anniversary Celebration

North Korea celebrates the 80th anniversary of the Socialist Patriotic Youth League with a grand performance, promoting youth unity and patriotism.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

Can GLP-1 Medications Reduce Breast Cancer Risk? New Research Reveals Surprising Findings

GLP-1 drugs show promise in cancer prevention and progression inhibition, expanding beyond obesity treatment to chronic disease management.

Revolutionary Discovery: How Environmental Stress Affects Cold Tumors and NK Cell Function

A study reveals cold tumors' causes extend beyond genetics to include environmental stress and lifestyle, impacting immune response.

Sillajen Presents Early BAL0891 Clinical Findings at ASCO 2026, Highlighting Safety and Early Anti-Cancer Activity

ShillaGen presented initial clinical research results of its cancer drug BAL0891 at ASCO, showcasing promising developments.

HLB to Spotlight Liver and Bile Duct Cancer Pipeline at ASCO 2026 With Standalone Global Booth

HLB will showcase liver cancer drug candidates at ASCO 2026, including promising combination therapies and precision medicine studies.

Lunit to Present Five AI Biomarker Studies at ASCO 2026 Highlighting Expanded Clinical Applications

Lunit will present five AI studies at ASCO 2026, showcasing biomarker analysis for cancer treatment and patient response prediction.

South Korea Expands HPV Vaccination Program to 12-Year-Old Boys as Experts Stress Broader Cancer Prevention

HPV vaccination now includes 12-year-old boys in South Korea, addressing rising infection rates and promoting awareness for both genders.

Samsung Medical Center Develops AI Technology to Predict Gallbladder Cancer Recurrence and Survival

Samsung Medical Center's AI technology predicts gallbladder cancer prognosis, aiding personalized treatment and improving patient outcomes.

AstraZeneca Highlights Decade of Tagrisso Progress in EGFR Mutation-Positive Lung Cancer Care

Tagrisso has revolutionized NSCLC treatment in Korea, expanding indications and improving survival rates over the past decade.

Boryung Begins First Global CDMO Supply of Alimta Through Taiwan Partnership

Boryung Pharmaceutical starts supplying Alimta to Lotus, enhancing global CDMO efforts and addressing chemotherapy drug shortages.

Yuhan to Receive $30 Million Milestone From European Launch of Lazertinib Combination Therapy

Yuhan Corporation receives a $30M milestone for Lazertinib's European launch, totaling $300M in payments, aiming for global healthcare leadership.

This New DNA Detection Breakthrough Could Change How Scientists Study Cancer Risk

KRISS and Wright State University developed a precise platform to detect ultra-trace damaged DNA, enhancing cancer research and treatment evaluation.

Samsung Biologics Highlights CRDO and Organoid Platforms at PEGS Boston

Samsung Biologics showcased its CRDO capabilities at PEGS Boston, enhancing cancer drug development with innovative organoid technology.

A New Study Suggests Selenium Could Help With One of Chemotherapy’s Most Disruptive Side Effects

A study reveals high-dose selenium can reduce exercise-related dysfunction in ovarian cancer patients undergoing chemotherapy.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.